A detailed history of Rafferty Asset Management, LLC transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 210,956 shares of VERV stock, worth $1.22 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
210,956
Previous 226,348 6.8%
Holding current value
$1.22 Million
Previous $1.1 Million 7.52%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$4.4 - $7.86 $67,724 - $120,981
-15,392 Reduced 6.8%
210,956 $1.02 Million
Q2 2024

Aug 13, 2024

SELL
$4.76 - $12.79 $1.18 Million - $3.16 Million
-247,235 Reduced 52.21%
226,348 $1.1 Million
Q1 2024

May 13, 2024

BUY
$10.81 - $17.96 $1.32 Million - $2.19 Million
121,679 Added 34.58%
473,583 $6.29 Million
Q4 2023

Feb 13, 2024

BUY
$8.84 - $18.7 $283,799 - $600,344
32,104 Added 10.04%
351,904 $4.91 Million
Q3 2023

Nov 13, 2023

BUY
$11.42 - $20.82 $455,452 - $830,343
39,882 Added 14.25%
319,800 $4.24 Million
Q2 2023

Aug 11, 2023

BUY
$13.34 - $19.9 $225,179 - $335,912
16,880 Added 6.42%
279,918 $5.25 Million
Q1 2023

May 11, 2023

SELL
$14.3 - $24.01 $1.57 Million - $2.63 Million
-109,643 Reduced 29.42%
263,038 $3.79 Million
Q4 2022

Feb 13, 2023

BUY
$17.85 - $40.7 $3.46 Million - $7.89 Million
193,914 Added 108.47%
372,681 $7.21 Million
Q3 2022

Nov 14, 2022

BUY
$15.63 - $41.49 $2.79 Million - $7.42 Million
178,767 New
178,767 $6.14 Million
Q2 2022

Aug 12, 2022

SELL
$11.14 - $23.17 $2.06 Million - $4.29 Million
-185,009 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$20.92 - $39.36 $871,004 - $1.64 Million
41,635 Added 29.04%
185,009 $4.22 Million
Q4 2021

Feb 10, 2022

BUY
$31.94 - $54.82 $4.58 Million - $7.86 Million
143,374 New
143,374 $5.29 Million

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $346M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.